Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

457.77 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 457.77
Bid (Size) 457.76 (2)
Ask (Size) 458.38 (9)
Prev. Close 457.77
Today's Range 457.77 - 457.77
52wk Range 333.07 - 550.76
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
Via Benzinga
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities

Performance

YTD
+22.46%
+22.46%
1 Month
-7.95%
-7.95%
3 Month
-11.56%
-11.56%
6 Month
+16.99%
+16.99%
1 Year
+19.10%
+19.10%

More News

Read More
Morgan Stanley Maintains Overweight Rating for argenx: Here's What You Need To Know
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
Micron To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
These 2 Stocks Are Falling in a Fading Rally
Via The Motley Fool
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Dutch Pharma Argenx Trading Lower Today?
Via Benzinga
Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug
Via Investor's Business Daily
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Exposures Product Safety
$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today
Via Benzinga
Earnings Outlook For argenx
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Via Benzinga
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth
Via InvestorPlace
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Via Investor's Business Daily
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses
Via Investor's Business Daily
Topics Earnings
Exposures Financial
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
From argenx SE
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.